Overview

Re-Radiochemotherapy and Pembrolizumab vs. Immuno(Chemo)Therapy for Locoregionally Recurrent PD-L1 Positive (CPS1) HNSCC

Status:
NOT_YET_RECRUITING

Trial end date:
2032-12-31

Target enrollment:

Participant gender:

Summary

Prospective, open-label, randomized controlled phase III trail that aims to investigate whether Re-Radiochemotherapy (Re-RCT) and sequential immunotherapy with pembrolizumab improves overall survival compared to the standard treatment with pembrolizumab alone ( chemotherapy) in locoregionally recurrent PD-L1 positive (CPS1) HNSCC.

Phase:

PHASE3

Details

Lead Sponsor:

Universitt des Saarlandes

Treatments:

Cisplatin
Fluorouracil
pembrolizumab
Radiotherapy